Yunnan Baiyao Group Co.Ltd(000538)
Minutes of investor research meeting
Time: March 31, 2022
Location: group headquarters office building
Holding method: teleconference
Investors: UBS asset management – Shi bin, Cui Cui, Chen Bingyu Haitong Securities Company Limited(600837) – Yu Wenxin, Zheng Qin, Meng Kehan
Participants: CEO Dong Ming, Secretary of the board Qian Yinghui, securities affairs representative Zhao Yan, securities affairs representative Zhu Ruiying, investor relations management GUI Boxiang, project management Li Mengjue
1. The composition of Academia Sinica and how to give play to the strategic driving force of each unit?
A: the Central Research Institute established by the company integrates Yunnan Baiyao Group Co.Ltd(000538) the core R & D institutions and R & D resources, including: (1) Yunnan Pharmaceutical Research Institute, which has a long history in the R & D of traditional Chinese medicine and is the core and leader of the company’s traditional Chinese Medicine innovation. The company will make long-term investment on this platform; (2) For the layout of the company in Beijing, the focus is to build Yunnan Baiyao Group Co.Ltd(000538) the R & D capacity, and take Peking University – Yunnan Baiyao Group Co.Ltd(000538) Xi’An International Medical Investment Company Limited(000516) research center as the platform for the company to explore the school enterprise cooperative R & D innovation mode, so as to complete the construction of strategic R & D organization system; (3) For the layout of the company in Shanghai, the focus is to build Yunnan Baiyao Group Co.Ltd(000538) the ability of product development and business expansion, Yunnan Baiyao Group Co.Ltd(000538) will build an integrated platform in Shanghai, layout an innovation incubation system and cultivate emerging business sectors.
2. Does the company’s strategy have a plan that can be implemented?
A: the company focuses on the “1 + 4 + 1” strategy to do a good job in enterprise transformation and development.
The “1” in the first “1 + 4 + 1” strategy refers to deeply cultivating the field of traditional Chinese medicine, using modern science to promote the development of the company’s traditional Chinese medicine products and boost the development of the traditional Chinese medicine industry. Specific measures include the secondary development of existing products, and supporting the sales promotion and application scope of these varieties through clinical trials. For example, we have received the notice of approval for drug clinical trials for quansanqi tablets disclosed in the previous stage, and will carry out clinical trials in various stages as required.
The second “4” refers to the four key development areas of the company, including oral area, skin area, bone injury area and female care area. The company’s positioning is not only to become a comprehensive solution provider in these fields, but also to become the leader and leader of these tracks. In these four established fields, the company’s product layout focuses on various forms of drugs, covering relevant devices and functional foods, and establishes a whole product matrix from prevention, detection, treatment to rehabilitation. Build the core competitiveness in the above fields through scientific exploration and methods.
The last “1” in the strategy of “1 + 4 + 1” is the index word technology. The company will introduce cutting-edge digital technology including artificial intelligence into all links of R & D and operation, and raise Yunnan Baiyao Group Co.Ltd(000538) ‘s product innovation and business operation ability to a new level.
In 2022, we will first launch a series of product combinations with solution characteristics in the fields of oral cavity and skin management.
3. What synergy can the strategic cooperation between the company and Shanghai Pharmaceuticals Holding Co.Ltd(601607) ?
A: the company has reached equity cooperation and strategic cooperation between the two sides by participating in the subscription of Shanghai Pharmaceuticals Holding Co.Ltd(601607) non-public offering of a shares. By virtue of Shanghai Pharmaceuticals Holding Co.Ltd(601607) high-quality platform and industrial resource coordination, the company has further amplified Yunnan Baiyao Group Co.Ltd(000538) existing resource advantages, grasped the important opportunities of industrial integration, expanded the scale of main business, the layout of existing industries, and improved the overall operation efficiency. Through regional complementarity, logistics, warehousing, purchase and price negotiation The integration and coordination of variety agency, brand promotion and new drug development is conducive to expanding the scale of main business, improving operation efficiency, and improving the core competitiveness and profitability of enterprises.
4. What is the plan of the company’s securities investment in 2022?
A: the company fully listens to the opinions and suggestions of the majority of investors on the development of the company, and strictly controls the investment scale of the secondary market on the basis of the original risk control measures. In 2022, within the limit approved by the board of directors, the company will gradually reduce its positions and will not continue to increase its holdings.
March 31, 2022
